<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The conditioning regimen prior to stem cell transplantation in 36 patients with high-risk <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) was intensified by treating patients with a <z:chebi fb="0" ids="49882">rhenium</z:chebi> 188-labeled anti-CD66 monoclonal antibody </plain></SENT>
<SENT sid="1" pm="."><plain>Dosimetry was performed prior to therapy, and a favorable dosimetry was observed in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="2" pm="."><plain>Radioimmunotherapy with the labeled antibody provided a mean of 15.3 Gy of additional radiation to the marrow; the kidney was the <z:mpath ids='MPATH_458'>normal</z:mpath> organ receiving the highest dose of supplemental radiation (mean 7.4 Gy) </plain></SENT>
<SENT sid="3" pm="."><plain>Radioimmunotherapy was followed by standard full-dose conditioning with total body irradiation (12 Gy) or <z:chebi fb="0" ids="28901">busulfan</z:chebi> and high-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> with or without thiotepa </plain></SENT>
<SENT sid="4" pm="."><plain>Patients subsequently received a T-cell-depleted allogeneic graft from a HLA-identical family donor (n = 15) or an alternative donor (n = 17) </plain></SENT>
<SENT sid="5" pm="."><plain>In 4 patients without an allogeneic donor, an unmanipulated autologous graft was used </plain></SENT>
<SENT sid="6" pm="."><plain>Infusion-related toxicity due to the labeled antibody was minimal, and no increase in treatment-related mortality due to the radioimmunoconjugate was observed </plain></SENT>
<SENT sid="7" pm="."><plain>Day +30 and day +100 mortalities were 3% and 6%, respectively, and after a median follow-up of 18 months treatment-related mortality was 22% </plain></SENT>
<SENT sid="8" pm="."><plain>Late renal toxicity was observed in 17% of patients </plain></SENT>
<SENT sid="9" pm="."><plain>The relapse rate of 15 patients undergoing transplantation in first CR (complete remission) or second CR was 20%; 21 patients not in remission at the time of transplantation had a 30% relapse rate </plain></SENT>
<SENT sid="10" pm="."><plain>(Blood </plain></SENT>
<SENT sid="11" pm="."><plain>2001;98:565-572) </plain></SENT>
</text></document>